Egb 761®
Cognitive Disorder
Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Ipsen
Modality
UNKNOWN
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00814346CT.gov Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions | — | Completed | — | — | — |
NCT00276510CT.gov A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cognitive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Egb 761® (this asset) | Ipsen | Approved | BB · 69 |
| Nicotine | University of Southern California | P2 | BBB |
| Oxybutynin | University of Alberta | P4 | BBB |
| Quetiapine | Emory University | P4 | BB |
| Rivastigmine | VA Office of Research and Development | P4 | BB |
| Levodopa | Vanderbilt University Medical Center | P4 | BB |
| Metformin | Fudan University | P4 | BB |
| Ginkgo Biloba Extract | Hanyang University | P4 | BB |
| Benzeneethanamine, N-Ethyl-?-Methyl-4-(Trifluoromethyl)-, Hydrochloride, (±)- | University of Oxford | P4 | BB |
+42 more in the Cognitive Disorder cohort
Other indications for Egb 761®
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Stroke Disorder | — | P3 | BB · 64 |
| Nervous System Disorder | — | P3 | BB · 64 |
| Relapsing-Remitting Multiple Sclerosis | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Egb 761® in Cognitive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/egb-761-cognitive-disorder-70856
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →